医学
前列腺癌
抗原
细胞因子释放综合征
T细胞
内科学
肿瘤科
癌症
免疫系统
嵌合抗原受体
免疫疗法
癌症研究
免疫学
作者
Tanya Barauskas Dorff,M. Suzette Blanchard,Lauren N. Adkins,Laura Luebbert,Neena A. Leggett,Stephanie N. Shishido,Alan Macias,Marissa Morales Del Real,Gaurav Dhapola,Colt A. Egelston,John Paul Murad,Reginaldo Cruz Alves Rosa,Jinny A. Paul,Ammar Ahmed Chaudhry,Hripsime Martirosyan,Ethan A. Gerdts,Jamie R. Wagner,Tracey Stiller,Dileshni Tilakawardane,Sumanta Kumar Pal
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2024-06-01
卷期号:30 (6): 1636-1644
被引量:145
标识
DOI:10.1038/s41591-024-02979-8
摘要
Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have demonstrated durable remissions in hematological malignancies. We report results from a phase 1, first-in-human study of prostate stem cell antigen (PSCA)-directed CAR T cells in men with mCRPC. The starting dose level (DL) was 100 million (M) CAR T cells without lymphodepletion (LD), followed by incorporation of LD. The primary end points were safety and dose-limiting toxicities (DLTs). No DLTs were observed at DL1, with a DLT of grade 3 cystitis encountered at DL2, resulting in addition of a new cohort using a reduced LD regimen + 100 M CAR T cells (DL3). No DLTs were observed in DL3. Cytokine release syndrome of grade 1 or 2 occurred in 5 of 14 treated patients. Prostate-specific antigen declines (>30%) occurred in 4 of 14 patients, as well as radiographic improvements. Dynamic changes indicating activation of peripheral blood endogenous and CAR T cell subsets, TCR repertoire diversity and changes in the tumor immune microenvironment were observed in a subset of patients. Limited persistence of CAR T cells was observed beyond 28 days post-infusion. These results support future clinical studies to optimize dosing and combination strategies to improve durable therapeutic outcomes. ClinicalTrials.gov identifier NCT03873805 .
科研通智能强力驱动
Strongly Powered by AbleSci AI